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Background: Little is known about health-related quality of life (HRQOL) following
treatment for bladder cancer (BC).
Objective: To determine this, we undertook a cross-sectional survey covering 10% of the
English population.
Design, setting, and participants: Participants 1–10 yr from diagnosis were identified
through national cancer registration data.
Intervention: A postal survey was administered containing generic HRQOL and BC-
specific outcome measures. Findings were compared with those of the general popula-
tion and other pelvic cancer patients.
Outcome measurements and statistical analysis: Generic HRQOL was measured using
five-level EQ-5D (EQ-5D-5L) and European Organization for Research and Treatment of
Cancer quality of life questionnaire (EORTC QLQ)-C30. BC-specific outcomes were
derived from EORTC QLQ-BLM30 and EORTC QLQ-NMIBC24.
Results and limitations: A total of 1796 surveys were completed (response rate 55%),
including 868 (48%) patients with non–muscle-invasive BC, 893 (50%) patients who
received radiotherapy or radical cystectomy, and 35 (1.9%) patients for whom treatment
was unknown. Most (69%) of the participants reported at least one problem in any EQ-5D
dimension. Age/sex-adjusted generic HRQOL outcomes were similar across all stages
and treatment groups, whilst problems increased with age (problems in one or more EQ-
5D dimensions: <65 yr [67% {95% confidence interval or CI: 61–74}] vs 85+ yr [84% {95%
CI: 81–89}], p = 0.016) and long-term conditions (no conditions [53% {95% CI: 48–58}] vs
more than four conditions [94% {95% CI: 90–97}], p < 0.001). Sexual problems were
reported commonly in men, increasing with younger age and radical treatment. Younger
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participants (under 65 yr) reported more financial difficulties (mean score 20 [95% CI:
16–25]) than those aged 85+ yr (6.8 [4.5–9.2], p < 0.001). HRQOL for BC patients (for
comparison, males with problems in one or more EQ-5D dimensions 69% [95% CI: 66–
72]) was significantly worse than what has been found after colorectal and prostate
cancers and in the general population (51% [95% CI: 48–53], all p < 0.05).
Conclusions: HRQOL following BC appears to be relatively independent of disease stage,
treatment, and multimodal care. Issues are reported with sexual function and financial
toxicity. HRQOL after BC is worse than that after other pelvic cancers.
Patient summary: Patients living with bladder cancer often have reduced quality of life,
which may be worse than that for other common pelvic cancer patients. Age and other
illnesses appear to be more important in determining this quality of life than the
treatments received. Many men complain of sexual problems. Younger patients have
financial worries.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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In 2018, 500 000 new cases of bladder cancer (BC) were
diagnosed worldwide [1]. BC encompasses a spectrum of
disease, from indolent non–muscle-invasive BC (NMIBC)
with a long natural history [2] to aggressive muscle-invasive
BC (MIBC) requiring radical surgery, radiotherapy (RT), and
chemotherapy [3,4]. Patients have variable life expectancies
due to competing comorbidities [5]. Of the three key
questions that matter to cancer patients (survival, experi-
ence of care [6,7], and future quality of life [8]), there are
significant gaps in our understanding of health-related
quality of life (HRQOL). Most HRQOL reports have focussed
on survivors of MIBC [9,10], in whom radical cystectomy
(RC) or radical RT impact urinary [11], bowel [12], and
sexual function [13,14] and body image [15,16]. Deficits in
social interactions, physical activity, and emotional function
have been described [17]. Little is known about HRQOL
following diagnosis of NMIBC [18,19], longer-term BC
outcomes, and how these patients compare with other
cancer patients.
Robust, large-scale, patient-centred studies are vital to
fully understand outcomes, inform treatment options,
and deliver services to support unmet needs [20]. Most
studies on patient-reported outcome measures (PROMs)
for BC have been small, with limited follow-up [21]. In a
pilot study of patients 1–5 yr after diagnosis [17], we
identified better HRQOL in patients with NMIBC who
received adjuvant treatments rather than just endoscopic
surgery. Lowest HRQOL was found for patients receiving
RT for advanced BC (problems with mobility, self-care,
performing usual activities, and urinary frequency; and
more likely to be socially distressed, lack energy, and be
unable to work compared with others). However, this
work collected limited treatment information, used
generic PROM tools, and did not allow comparison with
other cancer groups.
Our primary objective was to define, at a population
level, the HRQOL of individuals living with and beyond BC
diagnosed within the previous 10 yr. Our secondary
objective was to compare this HRQOL with that in other
pelvic cancer patients and the general population.2. Patients and methods
2.1. Study design and setting
A cross-sectional survey of individuals 1–10 yr after BC diagnosis was
performed during January 2007–December 2016 (as detailed by Mason
et al [9]). Eligible patients were diagnosed in National Health Service
(NHS) hospitals within Yorkshire and Humber, North Derbyshire, or
South Tees regions of England (area covering approximately 5.9 million
persons [11% of the total English population]), with 22 hospitals
providing urological services (Supplementary Fig. 1). Individuals were
identified through the National Cancer Registration and Analysis Service
(NCRAS) and excluded if under 18 yr of age, serving a custodial sentence
(in Her Majesty’s Prison Service), or had registered objection to
participating in research (type 2 with NHS Digital) [22]. Survey
administration was coordinated by an NHS-approved independent
survey provider (Quality Health Ltd., Unit 1, Holmewood Business Park,
Chesterfield Road, Holmewood, Chesterfield S42 5US, UK). Participants
consented by returning a completed questionnaire or declined by not
responding, returning an unanswered survey, or opting out via a
Freephone helpline. Options to participate online or by phone were
available.
2.2. Survey content
The survey (Supplementary material) included questions about the
participant’s sociodemographics, presence of other long-term conditions
(LTCs), and treatment received. Generic HRQOL was assessed with the
five-level EQ-5D (EQ-5D-5L) [23,24] and European Organization for
Research and Treatment of Cancer quality of life questionnaire (EORTC
QLQ)-C30 [25]. BC treatment–specific outcomes were assessed using
EORTC QLQ-NMIBC24 [18] and EORTC QLQ-BLM30 [26]. The EQ-5D-5L
covers five dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression), plus a 0–100 rating of self-assessed
health (SAH). EQ-5D-5L comparative data are available from other large
studies on prostate [27] and colorectal cancer PROMs [28] and
population survey [29]. EORTC QLQ-C30 consists of five functional
scales, three symptom scales, and six single items assessing symptoms
(including financial impact and a global scale of quality of life) [25]. For
BC-specific assessment relevant to both NMIBC and MIBC, whilst limiting
item duplication and participant burden, we obtained permission to
combine the two EORTC questionnaires QLQ-BLM30 and QLQ-NMIBC24
(N. Aaronson, personal communication, 2017). The final merged
questionnaire contained 34 questions comprising eight scales and single
items (Supplementary material). Table 1 provides an overview of the
outcome measures, and their scoring and interpretation.
Table 1 – Overview of patient-reported outcome measures in our questionnaire




EQ-5D-5L 5 items assessing mobility, self-
care, usual activities, pain/
discomfort, and anxiety/depression
5-point scale: 1 (no





reporting at least one
problem (any severity) on
any domain and those
reporting no problems
EQ-5D visual analogue scale Single item rating overall self-
assessed heath
0 (worse) to 100 (best)
scale of health you can
imagine
Higher score = better QOL 7 points
Cancer-specific QOL
EORTC QLQ-C30 5-functional scales measuring
physical, emotional, cognitive,
social, and role
4-point scale: 1 (not at all)
to 4 (very much)
All EORTC responses are
linearly transformed to 0–
100 scales. Higher
score = better functioning
10 points
3-symptom scales measuring
fatigue, pain, and nausea/vomiting
4-point scale: 1 (not at all)
to 4 (very much)
Higher score = worse
symptoms
Single items assessing symptoms
(dyspnoea, insomnia, appetite,
constipation, diarrhoea) and
financial impact of cancer
4-point scale: 1 (not at all)
to 4 (very much)
Higher score = worse
symptoms
2 items assessing global health
status
7-point scale: 1 (very poor)
to 7 (excellent)
Higher score = better QOL
Treatment and cancer-specific QOL
Combined EORTC QLQ-
BLM30 and QLQ-NMIBC24
(34 items in total)*
Urinary symptoms scale (7 items) 4-point scale: 1 (not at all)
to 4 (very much)
Higher scores = worse
symptoms/more problems
for all scales and items
excluding sexual function
and enjoyment
Urostomy problems (6 items)
Catheter use problems (1 item)
Intravesical treatment issues
(1 item)
Bloating and flatulence scale
(2 items)
Malaise scale (2 items)
Body image scale (3 items)
Sexual function scale (2 items) Higher scores = better
functioning
Sexual enjoyment (single item) Higher scores = more
enjoyment
Sexual intimacy (1 item)
Male sexual problems (2 items)
Female sexual problems (1 item)
Risk of contaminating partner
(1 item)
Future worries scale (4 items)
EORTC = European Organization for Research and Treatment of Cancer; HRQOL = health-related quality of life; QOL = quality of life.
Permission obtained from EORTC to combine items from QLQ-BLM30 and QLQ-NMIBC24.
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Responses were linked to patient, tumour, and treatment data collected
by NCRAS, including extracts from national cancer registration,
Hospital Episodes Statistics, Radiotherapy Data Set, and Systemic
Anti-Cancer Therapy datasets. Using a combination of these datasets,
respondents were categorised into treatment groups (Supplementary
Table 1). RT regimens were classified according to radical and palliative
intent [30].2.4. Statistical analysis
Descriptive statistics were used to report respondent characteristics and
questionnaire responses. Age was grouped into <65, 65–74, 75–85, and
85 yr. The number of LTCs was counted and categorised into groups
with none, one, two or three, or four or more LTCs. EQ-5D-5L responses
were split into groups of those by individuals who reported one or more
problems (of any severity) on each dimension and by individuals who
reported no problems. Mean SAH ratings (0–100) were calculated. The



















Age IQR Age IQR Age IQR Age IQR Age IQR Age IQR
Median age at diagnosis 70 64–76 71 64–78 69 63–75 69 62–75 68 63–72 74 67–78 <0.001
Median age at survey 76 70–82 78 71–84 76 70–82 75 69–80 74 70–78 79 73–84 <0.001
N % N % N % N % N % N %
Sex Male 1,376 76.6 235 76.8 449 79.9 296 73.1 224 74.9 125 80.7 0.090




None 433 24.1 76 24.8 122 21.7 111 27.4 79 26.4 29 18.7 0.168
1 545 30.4 84 27.5 176 31.3 121 29.9 96 32.1 47 30.3
2 384 21.4 61 19.9 113 20.1 92 22.7 62 20.7 38 24.5
3 237 13.2 48 15.7 80 14.2 42 10.4 42 14.0 21 13.6
4 197 11.0 37 12.1 71 12.6 39 9.6 20 6.7 20 12.9
Socioeconomic deprivation 1—least deprived 397 22.1 62 20.3 135 24.0 85 21.0 67 22.4 28 18.1 0.838
2 457 25.5 71 23.2 136 24.2 99 24.4 84 28.1 46 29.7
3 378 21.1 67 21.9 120 21.4 85 21.0 62 20.7 37 23.9
4 273 15.2 49 16.0 84 15.0 68 16.8 38 12.7 19 12.3
5—most deprived 291 16.2 57 18.6 87 15.5 68 16.8 48 16.1 25 16.1
Stage at diagnosis I 773 43.0 195 63.7 333 59.3 149 36.8 57 19.1 20 12.9 <0.001
II 203 11.3 – 2.3 – 1.3 53 13.1 62 20.7 66 42.6
III 69 3.8 – 1.0 – 0.2 37 3.1 17 5.7 – 6.5
IV 57 3.2 – 1.0 – 0.2 17 4.2 24 8.0 – 4.5
Unknown 694 38.6 98 32.0 220 39.2 149 36.8 139 46.5 52 33.6
BCG=bacillus Calmette-Guerin; IQR= interquartile range; MMC= intravesical mitomycin C; RC= radical cystectomy; RT = radiotherapy; TURBT= transurethral resection of a bladder tumour.
a Including radical cystectomy with intravenous chemotherapy (77%), intravenous chemotherapy and radiotherapy (6%) or immunotherapy (5%), and radiotherapy (1%) or immunotherapy (10%).
b Four patients received <52Gy but were classified by consensus as radical (one received 44Gy in 22 fractions and three received 50Gy in 20 fractions).
































E U R O P E A N U R O L O G Y 7 9 ( 2 0 2 1 ) 6 2 1 – 6 3 2 625EORTC QLQ-C30 and merged BC modules were linearly transformed to a 0–
100 scale, as per the scoring manual, with mean scores calculated for all
scales and single items. EQ-5D, QLQ-C30, and the merged EORTC BC module
outcomes were analysed by the treatment group, with adjustment for age
and sex (using multivariable logistic regression for EQ-5D binary outcomes
and multivariable linear regression for SAH, QLQ-C30, and the merged
EORTC bladder modules). In addition, outcomes for each treatment group
were stratified by age group. Where relevant, differences in scores between
groups were assessed using previously defined clinically meaningful
differences (a difference of 7 points for EQ-5D SAH [27] and 10 points for
QLQ-C30 [31]). BC HRQOL scores were compared with the available PROM
datasets for patients with prostate [27] and colorectal cancer [28], and the
general population [29]. Analyses were performed using Stata version 16
(Stata Corp., College Station, TX, USA).
2.5. Ethical and regulatory approval
This study received the following approvals: Yorkshire & Humber, South
Yorkshire Research Ethics Committee (17/YH/0095), Health Research
Authority Confidentiality Advisory Group (17/CAG/0054); Office for Data
Release (ODR1718_089), and NHS Digital Data Access Request Service
(DARS-NIC-129819-V5P5Z-v2.4).
2.6. Patient and public involvement
Patient and public involvement was embedded in study design and
delivery. Initial focus groups helped develop the study concept. Patient
feedback contributed to refining patient-facing information and gaining
necessary ethical and governance approvals. Throughout the study,
patient representatives attended advisory group meetings and helped
with the interpretation of the results. Two patient representatives are
contributing authors of this manuscript.
3. Results
3.1. Participants, response rates, and treatments
Overall, 3279 eligible participants were identified, of whom
19 died during the survey period and 1796 returned a
completed survey (completion rate: 55% [1796/3260],
including 29 online and 13 telephone completions).
Compared with survey responders, nonresponders were
older, lived in more deprived areas, and were more likely to
have unknown disease stage (all p < 0.01, Supplementary
Table 2). Men and women were equally likely to respond.
Question completeness was high (>95%) for all components
of EQ-5D-5L and QLQ-C30, but lower for items relating to
sexual issues, for example, sexual intimacy (39% comple-
tion), sexual enjoyment (36%), and female sexual problems
(28%; Supplementary Table 3).
Over three-quarters of respondents were male (77%), and
the average age at diagnosis was 69 yr (Table 2). At the time
of survey, the average age of respondents was 75 yr (11%
aged <65 yr). Coexisting LTCs were common; 76% reporting
at least one and 11% reporting four or more. The most
common LTCs were hypertension (24%), coronary artery
disease (14%), and diabetes (11%). Only 1.0% of respondents
were nonwhite in racial origin.
At diagnosis, NCRAS staged 43% of tumours as NMIBC and
18% as MIBC, and 39% did not have a stage recorded. Using
information from the linked datasets, 48% (n = 868) ofrespondents had treatment for NMIBC (transurethral resec-
tion of bladder tumour [TURBT]  intravesical treatment), 50%
(n = 893) had radical treatment (RT or RC), and in 1.9% (n = 35)
treatment was unknown (Supplementary Table 1). Of those
receiving radical treatment, 47% (n = 405/859) underwent RC
alone (following TURBT), 35% (n = 299) had radical surgery
with other treatments (such as intravenous [IV] neoadjuvant
chemotherapy or prior intravesical bacillus Calmette-Guerin
[BCG]), and 18% (n = 155) received RT with radical intent.
Excluding stage (which is directly linked to treatment), only
age varied significantly  across the treatment groups; partici-
pants receiving RT were older at diagnosis (median: 74 yr)
than those undergoing RC or TURBT (median: 69 yr, p < 0.001;
Table 2). Finally, 14 participants received palliative RT and
20 received only IV chemotherapy. Given the expected low
number in this cohort, we excluded the palliative population
from treatment-specific  analysis.
3.2. General HRQOL: EQ-5D-5L
Over two-thirds of respondents (69%) reported at least one
problem in any EQ-5D-5L dimension. Most problems were
reported for mobility, followed by usual activities and pain.
The overall mean SAH rating was 74/100. Outcomes were
similar across all stages and treatment groups (Fig. 1A and 1B,
and Supplementary Table 4). For example, after adjustment
for age and sex, SAH ranged from 75 (95% confidence interval
[CI]: 73–77) in the RC alone group to 71 (95% CI: 68–74) in the
radical RT group. When stratified by treatment modality
(Fig. 1C–H), the frequency of reported problems increased in
all dimensions with increasing age and number of LTCs, with
the exception being anxiety/depression, which was highest in
the younger age groups. Multimodal treatment combinations
did not impact HRQOL (no differences were seen between
patients who received TURBT with/without intravesical
treatment and those who received RC with/without other
treatments).
3.3. Cancer generic HRQOL: EORTC QLQ-C30
The mean global health score was 71/100. This ranged from
72 (95% CI: 70–75) after RC to 69 (95% CI: 65–72) after
radical RT (age/sex adjusted). No meaningful differences in
scales or symptom scores were seen between the treatment
groups or by stage (Fig. 2A and 2B, and Supplementary
Table 5). Across treatments (Fig. 2C–H), as with EQ-5D-5L,
worse function and symptom scores were seen with
increasing age and LTC burden. One notable outlier was
the higher rate of financial difficulties reported by younger
patients: <65 yr old (mean 20 [95% CI: 15–25]) versus
65 yr old (6.6 [95% CI: 4.9–8.2]). Of note, these financial
difficulties were greater in younger patients undergoing RC
(mean 26 [95% CI: 19–33]) than in those undergoing TURBT
(15 [95% CI: 9.1–22]).
3.4. Treatment-specific HRQOL: EORTC BC modules
EORTC bladder symptom scores varied considerably across
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Fig. 1 – HRQOL using the EQ-5D-5L questionnaire. Percentage of patients with a problem in one or more EQ-5D-5L dimensions and scores for self-
assessed health (SAH), all adjusted for age and sex, and presented for (A) each treatment and (B) tumour stage (using cancer registration data).
Percentage of patients with a problem in one or more EQ-5D-5L dimensions and SAH scores stratified by age and number of long-term conditions
(LTCs) in participants who received (C and D) TURBT for NMIBC (including those who also received additional treatments), (E and F) radical cystectomy
(including those who also received additional treatments), and (G and H) radical radiotherapy for MIBC (including those who also received additional
treatments). Error bars indicate 95% confidence intervals.
Cyst = cystectomy; HRQOL = health-related quality of life; MIBC = muscle-invasive bladder cancer; NMIBC = non–muscle-invasive bladder cancer;
Rad = radical; RT = radiotherapy; TURBT = transurethral resection of bladder tumour.
E U R O P E A N U R O L O G Y 7 9 ( 2 0 2 1 ) 6 2 1 – 6 3 2626Supplementary Table 6), and when treatments were
stratified by age and LTCs (Fig. 3C–F). In participants who
received RT, changes in most symptom scores were less
directly associated with age (Fig. 3G).
Worse urinary symptoms were reported following
radical RT (mean 32 [95% CI: 28–36]) compared with
TURBT (24 [95% CI: 22–26], age/sex adjusted p < 0.001).
Urinary symptoms in participants following RC with
neobladder (25 [95% CI: 19–31]) were similar to those
following TURBT. Addition of intravesical treatments to
TURBT did not worsen urinary symptoms or increase
concerns about contaminating partners when compared
with TURBT (Fig. 3A).Across treatment groups, respondents who underwent
RC (alone or in combination) reported worse problems with
body image, sexual intimacy, sexual enjoyment, and male
sexual problems (Fig. 3A). In patients who underwent
TURBT, sexual function and enjoyment declined with age
and increasing LTCs, whilst sexual problems increased
(Fig. 3C and 3D). In males who underwent RC, whilst all
symptom scores worsened with increasing age, the most
dramatic changes were for sexual function, sexual intimacy,
and male sexual problem scores (Fig. 3E). Sexual problems
in females could not be evaluated accurately due to high
rates of missing data (28% completion rate; Supplementary
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Fig. 2 – HRQOL using the EORTC QLQ-C30 questionnaire. Mean (95% CIs) scores (0–100) for each scale, adjusted for age and sex, are shown for the
whole population and presented by (A) each treatment and (B) tumour stage (using cancer registration data). Mean scores, stratified by age and
number of long-term conditions (LTCs), in participants who received (C and D) TURBT for NMIBC (including those who also received additional
treatments, (E and F) radical cystectomy (including those who also received additional treatments), and (G and H) radical radiotherapy for MIBC
(including those who also received additional treatments). Error bars indicate 95% confidence intervals.
CI = confidence interval; Cyst = cystectomy; HRQOL = health-related quality of life; MIBC = muscle-invasive bladder cancer; NMIBC = non–muscle-invasive
bladder cancer; Rad = radical; RT = radiotherapy; TURBT = transurethral resection of bladder tumour.
E U R O P E A N U R O L O G Y 7 9 ( 2 0 2 1 ) 6 2 1 – 6 3 2 627the RC population were underpowered (neobladder, n = 88
and ileal conduit, n = 616) and potentially mismatched (eg,
those receiving neobladder were younger [median age 66 vs
75 yr for ileal conduit] and had fewer LTCs [no LTCs: 41% vs25% for ileal conduit, and more than two LTCs: 23% vs 45%
for ileal conduit]), but suggested few changes beyond

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3 – Merged EORTC QLQ-NMIBC24 and EORTC QLQ-BLMC30 scores. Mean (95% CIs) scores (0–100) for each scale, adjusted for age and sex, are
shown for the whole population and presented by (A) each treatment and (B) tumour stage (using cancer registration data). Mean scores, stratified by
age and number of long-term conditions (LTCs), in participants who received (C and D) TURBT for NMIBC (including those who also received additional
treatments), (E and F) radical cystectomy (including those who also received additional treatments), and (G and H) radical radiotherapy for MIBC
(including those who also received additional treatments). Error bars indicate 95% confidence intervals.
CI = confidence interval; Cyst = cystectomy; EORTC QLQ = European Organization for Research and Treatment of Cancer quality of life questionnaire; MIBC = muscle-
invasive bladder cancer; NMIBC = non–muscle-invasive bladder cancer; Rad = radical; RT = radiotherapy; TURBT = transurethral resection of bladder tumour.
E U R O P E A N U R O L O G Y 7 9 ( 2 0 2 1 ) 6 2 1 – 6 3 2628
E U R O P E A N U R O L O G Y 7 9 ( 2 0 2 1 ) 6 2 1 – 6 3 2 6293.5. Generic and treatment-specific HRQOL over time since
diagnosis
We observed little difference in the scores for each
questionnaire when analysed by time from diagnosis and
treatment (Supplementary Fig. 3).
3.6. Comparison of BC HRQOL with that in other pelvic cancer
patients and the general population
In comparison with the general population and groups with
prostate and colorectal cancer, our BC respondents (as a
whole) reported more problems across all EQ-5D-5L
dimensions, except for anxiety/depression, which was
comparable with that for colorectal and prostate cancer
(in men; Supplementary Table 7 and Supplementary Fig. 4).
The differences were greatest for problems with mobility
and usual activities. For example, 48% (95% CI: 46–52) of
men (male-only figures to facilitate direct comparison with
other common pelvic cancers) with BC reported problems
(of any level) with mobility compared with 36% (95% CI: 35–
37) of men with colorectal cancer, 34% (95% CI: 33–34) of
men with prostate cancer, and 25% (95% CI: 23–27) of the
male general population (adjusted for age and deprivation,
all comparisons p < 0.05). Pain/discomfort was worse in
men with BC (than the other populations), but similar for
females with BC and the general population.
4. Discussion
We report HRQOL in individuals up to 10 yr after a diagnosis
of BC. This is the largest study to date in this hard to reach,
under-reported disease group and delivers novel insights:
we have documented large variations in overall HRQOL by
age and LTCs, with fewer differences according to stage or
treatment received. Higher rates of sexual dysfunction were
reported, particularly by men, and financial toxicity was
reported in younger patients. Compared with the general
population and those with other common pelvic cancers, BC
patients had lower HRQOL.
Firstly, there were larger variations in long-term overall
HRQOL according to patient age and LTCs, rather than
treatment type, disease stage, or time since diagnosis. This
important observation has direct clinical relevance in
treatment decision-making, where robust evidence to
understand the trade-offs (in terms of overall survival
and quality of survival) between two approaches of
different extents is vital. Examples include the choice
between intravesical BCG and RC for high-grade NMIBC [32]
and between RC and RT for MIBC [33].
Secondly, treatment intensity and multimodality did not
appear to be associated with adverse HRQOL outcomes
(both generic and treatment-specific symptoms). For
example, participants who received TURBT alone or TURBT
with intravesical therapies had similar urinary symptoms
and sexual function scores. Participants who received RC
alone or RC with systemic chemotherapy had similar
functional and symptom scores across all domains (includ-
ing fatigue and gastrointestinal symptoms). Collectively,these data provide reassuring evidence for clinicians and
patients considering multimodal treatment options, and
justifies treatment choices based on symptoms, patient
preferences, and survival.
Thirdly, some of the highest problem scores were seen for
sexual function in men. Scores varied according to age, LTCs,
and treatment, suggesting a multifactorial origin. Participants
undergoing RC or RT have treatments that directly affect
erectile ability and ejaculation (and vaginal length in women).
The sexual impact of radical treatments is well known [13,14],
and should be managed by pretreatment counselling and
post-treatment support. High problem scores and patient
experience [7,34] suggest that this may often be omitted.
Surprisingly, we saw participants receiving TURBT (ie,
anatomical preserving treatment) had high scores for male
sexual problems and low scores for sexual function, intimacy,
and enjoyment. These scores were directly related to age and
LTC burden. The aetiology of sexual dysfunction in this
population probably reflects other health factors (similar to
transurethral resection of the prostate [35]) rather than BC or
side effects of BC treatment. However, interaction with health
care professionals should be seen as an opportunity to help
this cohort. One important observation was that most women
did not answer questions regarding female sexual issues. This
prevents us from drawing any observations in women and
warrants further investigation.
Fourthly, financial toxicity was reported by younger
patients receiving RC or TURBT [36]. Markedly lower rates
were reported by older persons receiving the same treat-
ments, which will be addressed in a subsequent publication
in detail, and suggests an impact of the disease and its
treatment on employment. Patterns of employment disrup-
tion differ between treatments; RC typically requires hospital
stay and 3-mo recovery [37], whilst TURBT pathways include
multiple outpatient visits (eg, 15 cystoscopies/treatments in
year 1 for maintenance BCG [38]). Many BC patients are
employed in manual work [39–41], and so are unable to work
whilst recovering from procedures or when suffering from
complications. Our survey was conducted in the UK (free
public health care) and may grossly under-represent this
issue in private health care systems.
Finally, a comparison of the overall HRQOL in BC patients
with that in prostate and colorectal cancer patients and a
matching general population revealed that all three cancer
cohorts had lower HRQOL than the general population, and
that BC participants had the lowest HRQOL of all. These
findings match with those of prior NHS England surveys [6]
reporting that BC cancer patients have poor experiences.
This likely reflects a lack of investment in supportive
aspects of their care, multiple visits necessary to manage BC,
and unchanging cancer outcomes [42]. Further research is
needed to understand these differences in more detail and
to compare with other pelvic cancers (such as ovarian
cancer; see http://www.ncin.org.uk/view?rid=2920]).
Our population-based approach, using cancer registration
data, enabled inclusion of all BC phenotypes and treatments,
without selection by hospital, speciality, trial participation, or
geographic location. Through the collection of generic and
specific HRQOL domains, utilising validated instruments, we
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groups and the general population, thereby facilitating
important and novel observations. Few data were missing
(the exception being questions related to sexual issues, which
had particularly low completion rates in females).
Limitations include that the ethnicity of respondents did
not fully represent the population of Yorkshire and Humber,
where over 10% are nonwhite British [43]. Further work is
mandated to explore the HRQOL of other ethnic groups.
Response rates were marginally lower than for similar UK
cancer surveys (63% for colorectal and 61% for prostate cancer)
[27,28], but similar to that reported by the Department of
Health, England, for BC patients (53%) [17] and so may reflect
this population (ie, typically more deprived, more manual
workers, [39–41], and lower literacy rates than other cancers
[44–46]). Nonrespondents were more likely to be older and
live in more socioeconomically deprived areas, groups that
may be expected to experience poorer HRQOL. Within the
registry data, we were unable to account for participants
whose tumours increased in stage (eg, progressed) and
around one-third of BCs had missing tumour stage. This rate is
higher than for other cancers and may reflect that UK
registries stage tumours as T1-T4, whilst many BCs are pTa
and pTis (a level of detail that could not be extracted). When
stratifying by treatment, the small radical RT cohort limited
some analyses (eg, there were fewer than five respondents
aged <65 yr and little information was known about RT/
maximal TURBT/chemotherapy use), as did the small number
of patients with neobladder formation after RC, and our lack of
knowledge regarding clinical outcomes or the time of last
treatment. Finally, following discussion with the EORTC
quality life group, to avoid duplication of content, we merged
the BC outcome measures (EORTC-QLQ BLM30 and EORTC-
QLQ NMIBC24) with the potential to disrupt their psychomet-
ric properties. This new approach is now being used by others
in on-going surveys [47].
5. Conclusions
HRQOL in individuals living with and beyond BC is worse
than that reported by the general population and those with
other common cancers, and appears to be independent of
therapy received and disease stage. The poor outcomes
largely reflect age and presence of other LTCs. Further in-
depth investigation of financial toxicity in those aged under
65 yr and sexual problems experienced by male and females
is necessary to guide risk stratification of aftercare support.
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